Elutia (ELUT) Competitors $1.92 +0.02 (+1.05%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.26%) As of 07/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. TNXP, FHTX, CADL, AURA, ABEO, PRTA, ATXS, ALT, AMRN, and PVLAShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Candel Therapeutics (CADL), Aura Biosciences (AURA), Abeona Therapeutics (ABEO), Prothena (PRTA), Astria Therapeutics (ATXS), Altimmune (ALT), Amarin (AMRN), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Its Competitors Tonix Pharmaceuticals Foghorn Therapeutics Candel Therapeutics Aura Biosciences Abeona Therapeutics Prothena Astria Therapeutics Altimmune Amarin Palvella Therapeutics Elutia (NASDAQ:ELUT) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Do analysts prefer ELUT or TNXP? Elutia presently has a consensus price target of $8.00, indicating a potential upside of 316.67%. Tonix Pharmaceuticals has a consensus price target of $70.00, indicating a potential upside of 40.79%. Given Elutia's higher possible upside, analysts clearly believe Elutia is more favorable than Tonix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of ELUT or TNXP? 74.0% of Elutia shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ELUT or TNXP? Elutia has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Does the media favor ELUT or TNXP? In the previous week, Elutia and Elutia both had 2 articles in the media. Elutia's average media sentiment score of 1.77 beat Tonix Pharmaceuticals' score of 0.62 indicating that Elutia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ELUT or TNXP? Elutia has higher revenue and earnings than Tonix Pharmaceuticals. Elutia is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElutia$24.38M3.24-$53.95M-$1.93-0.99Tonix Pharmaceuticals$10.09M36.27-$130.04M-$1.96 thousand-0.03 Is ELUT or TNXP more profitable? Elutia has a net margin of -168.23% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Elutia's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Elutia-168.23% N/A -96.70% Tonix Pharmaceuticals -1,313.87%-120.96%-101.28% SummaryElutia beats Tonix Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.12M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-0.9921.1828.1020.05Price / Sales3.24286.17429.0189.19Price / CashN/A42.7636.2258.56Price / Book-1.478.378.665.87Net Income-$53.95M-$55.19M$3.25B$258.55M7 Day Performance-9.43%5.88%4.22%3.73%1 Month Performance3.78%17.33%10.51%11.75%1 Year Performance-49.21%4.42%34.40%18.03% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.8021 of 5 stars$1.92+1.1%$8.00+316.7%-48.8%$78.12M$24.38M-0.99180Positive NewsUpcoming EarningsTNXPTonix Pharmaceuticals2.6031 of 5 stars$45.10-3.9%$70.00+55.2%-14.2%$345.13M$10.09M0.0050FHTXFoghorn Therapeutics2.142 of 5 stars$6.10-0.5%$12.13+98.8%-5.1%$341.70M$22.60M-4.49120News CoverageCADLCandel Therapeutics2.0909 of 5 stars$6.57-2.5%$22.00+234.9%+7.8%$337.69M$120K-4.9060AURAAura Biosciences2.4353 of 5 stars$6.77+0.9%$22.00+225.0%-29.6%$337.30MN/A-3.5650News CoveragePositive NewsABEOAbeona Therapeutics3.7543 of 5 stars$6.75+2.4%$19.25+185.2%+29.8%$337.12M$3.50M-5.3190PRTAProthena3.7494 of 5 stars$6.29+0.5%$31.50+400.8%-73.1%$336.96M$135.16M-3.02130ATXSAstria Therapeutics1.9173 of 5 stars$6.26+4.9%$30.00+379.2%-44.4%$336.91MN/A-3.3530ALTAltimmune2.0894 of 5 stars$4.05-0.7%$18.20+349.4%-39.0%$330.92M$20K-3.2150AMRNAmarin0.2424 of 5 stars$15.55-1.7%$12.00-22.8%-2.7%$327.58M$228.61M-4.27360Positive NewsUpcoming EarningsPVLAPalvella Therapeutics1.4301 of 5 stars$31.00+5.0%$47.50+53.2%N/A$326.25M$42.81M-2.56N/A Related Companies and Tools Related Companies TNXP Competitors FHTX Competitors CADL Competitors AURA Competitors ABEO Competitors PRTA Competitors ATXS Competitors ALT Competitors AMRN Competitors PVLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
